Yesterday, the EVP & CFO of Exelixis (EXEL), Christopher Senner, sold shares of EXEL for $173.2K.
In addition to Christopher Senner, 2 other EXEL executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Exelixis’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $225 million and quarterly net profit of $127 million. In comparison, last year the company earned revenue of $153 million and had a net profit of $81.16 million. EXEL’s market cap is $6.07B and the company has a P/E ratio of 17.21. Currently, Exelixis has an average volume of 3.57M.
Based on 7 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $27.50, reflecting a 35.4% upside.
The insider sentiment on Exelixis has been negative according to 64 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic.
